알덱사 테라퓨틱스(ALDX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.36 (-1.45%), 시가총액 $0.10B, 52주 최저~최고 $1.24 ~ $5.89.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, includi
알덱사 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
알덱사 테라퓨틱스의 현재 주가는 $1.36 (-1.45%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
알덱사 테라퓨틱스의 시가총액은 약 $0.10B입니다.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species